Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0M9RQ
|
||||
Former ID |
DIB018030
|
||||
Drug Name |
MK-0249
|
||||
Synonyms |
MK 0249; MK0249
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Obese insulin-resistant disorders [ICD9: 250; ICD10:E11] | Clinical trial | [1] | ||
Structure |
Download2D MOL |
||||
Formula |
C23H24F3N3O2
|
||||
InChI |
InChI=1S/C23H24F3N3O2/c1-16-27-20-7-4-6-19(23(24,25)26)21(20)22(30)29(16)17-8-10-18(11-9-17)31-15-5-14-28-12-2-3-13-28/h4,6-11H,2-3,5,12-15H2,1H3
|
||||
InChIKey |
DDDZBLNULGDPGA-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Histamine H3 receptor | Target Info | Agonist | [2] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Reactome | Histamine receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Monoamine Transport | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | (11)C-MK-8278 PET as a tool for pharmacodynamic brain occupancy of histamine 3 receptor inverse agonists. J Nucl Med. 2014 Jan;55(1):65-72. | ||||
REF 2 | Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. J Med Chem. 2008 Aug 14;51(15):4780-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.